We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Pfizer must finalise their bid for AZ by May 26. If t/o goes ahead danger of loss of jobs in Cambridge life sciences area. Seems more likely Pfizer want AZ to ease their US tax burden and will go ahead with proposed construction of research facility in Cambridge providing employment for 20 000. If latter perhaps Silicon Fen will become SilicoBio Fen in near future?
picked up a few of these at IPO been rather underwhelmed so far but keeping the faith - anyone want to share their views or any info?
This was almost seven times oversubscribed and a record high for a Cambridge biotech on AIM: It is also in the top five largest IPOs ever by a non-therapeutic UK biotech. The group has a broad international customer base including pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centres around the world. 2013 revenues were derived from 353 unique customers including AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, Merck & Co., Novartis Institute of Biomedical Research and Takeda. Horizon’s proprietary translational genomics platform, GENESIS™ – comprising three gene-editing tools: rAAV (under exclusive licence), ZFN (under non-exclusive licence) and CRISPR (under non-exclusive licence) – offers a precise and flexible gene-editing solution. The group operates a powerful business model, differentiated from typical biotechnology companies, where it can leverage both internally-funded and customer-funded cell line development, drug discovery services and cell line and derivative reagent product offerings. Additional leverage is achieved by combining the offering with novel IP, oncology and drug discovery expertise allowing the Group to accrue downstream milestones and the potential for product royalties. Horizon supplies its services and products into multiple markets, including the translational genomics research market; the cell based assays market; the molecular diagnostics market; and the bioproduction market. Combined, the directors estimate these markets to total more than £29 billion ($48bn) by 2015. Horizon plans to use the cash to broaden its product portfolio and service offering as well for aggressive territorial expansion globally. .
Does anyone have any views on the potential of this one?